Introduction HER2-targeted therapy improves outcomes of HER2-positive endometrial cancer (EC). A novel class of HER2-directed antibody drug conjugate (ADC) that has demonstrated significant benefit in HER2-Low breast carcinoma, is being evaluated in clinical trials for other solid tumors, including uterine carcinoma with varying levels of HER2 expression. ADC efficacy in HER2-Low cancers may be partially attributed to bystander effect in tumors with heterogenous HER2 expression. We characterize the spectrum of HER2 expression in EC cases tested in a large tertiary care centre.
Methods An audit of HER2 testing in EC was conducted, utilizing ISGyP criteria for immunohistochemistry (IHC) scoring. Akin to the DESTINY clinical trials, HER2-P (positive) was defined as IHC score 3+ or FISH-amplified; HER2-L (low) defined as IHC2+ (not-amplified) or IHC1+ and HER2-N (negative) defined as IHC score 0.
Results There were 95 primary, 4 local recurrences and 10 metastatic EC HER2 tests, with 33 (30%) HER2-N, 46 (42%) HER2-L and 30 (28%) HER2-P. 60 were serous carcinoma, 29 high-grade EC, 9 carcinosarcomas, 8 Endometrioid and 3 others. Among 79 p53 abnormal cases, 22 (28%), 34 (43%), 23 (29%) were HER2-N, HER2-L and HER2-P, respectively. Table 1 summarizes p53, MMR and ER status by IHC and presence of pathogenic POLE mutations. None of the POLE-mutated or MMR-deficient molecular subgroup cases were HER2-P.
Conclusion/Implications The majority of ECs tested by IHC/FISH demonstrated some level of HER2 expression, with 42% meeting the criteria for HER2-L designation, potentially doubling the patients that may be considered for novel ADC therapies compared to the legacy HER2 targeted therapies.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.